After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more

StreetInsider2021-10-19

After-Hours Stock Movers: Entasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

W00dy
2021-10-19
W00dy
Like pls, thanks
- JeremyKok:
  hi. please like and comment back. thank you.
SanWangtikup
2021-10-19
SanWangtikup
Like pls
- JeremyKok:
  hi. please like and comment back. thank you.
LennartM
2021-10-19
LennartM
like please
- JeremyKok:
  hi. please like and comment back. thank you.
- Blackbunny:
  done
Chris68
2021-10-19
Chris68
Good to know
- Chris68:
  Yup
Bentofighter
2021-10-19
Bentofighter
Pls like
- JeremyKok:
  hi. please like and comment back. thank you.
Cindyoxy
2021-10-19
Cindyoxy
Like pls
- JeremyKok:
  hi. please like and comment back. thank you.
- Bentofighter:
  Ok
- LennartM:
  done

发表看法

255

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2176774120?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-19 07:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2176774120","market":"us","top_or_hot":-1,"title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","media":"StreetInsider","content":"<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">网页链接</a>\n\n</div>\n","source":"highlight_streetinsider","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","article_id":"2176774120","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","pubTimestamp":1634599410,"sourceInfo":{"source_id":"highlight_streetinsider","name":"StreetInsider"},"weMediaInfo":null,"summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","collect":0,"end_time":0,"defaultTopTitle":"streetinsider.com","property":[],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"下班后股票搬运工：Entasis疗法、皮肤疗法、TaskUs等","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DRMA":0.9,"ETTX":0.9,"EVER":0.9,"STLD":0.9,"TASK":0.9},"content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":859026057,"gmtCreate":1634641801928,"gmtModify":1634641802495,"author":{"id":"4089162592476240","authorId":"4089162592476240","name":"W00dy","avatar":"https://static.tigerbbs.com/e321bf45dd05336a6b9f1c27eb0ecde8","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"4089162592476240","idStr":"4089162592476240"},"htmlText":"Like pls, thanks","listText":"Like pls, thanks","text":"Like pls, thanks","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859026057","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","TASK":"TaskUs Inc.","EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294365,"gmtCreate":1634947223999,"gmtModify":1634947224031,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":859026057,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":859034194,"gmtCreate":1634636780745,"gmtModify":1634636948850,"author":{"id":"4087452914358580","authorId":"4087452914358580","name":"SanWangtikup","avatar":"https://static.tigerbbs.com/c7f061d50a9f915d0ce8e8c879871960","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"4087452914358580","idStr":"4087452914358580"},"htmlText":"Like pls&nbsp;","listText":"Like pls&nbsp;","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/859034194","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","TASK":"TaskUs Inc.","EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294369,"gmtCreate":1634947232278,"gmtModify":1634947232317,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":859034194,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850404496,"gmtCreate":1634613429819,"gmtModify":1634613430763,"author":{"id":"3576017931077934","authorId":"3576017931077934","name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3576017931077934","idStr":"3576017931077934"},"htmlText":"like please","listText":"like please","text":"like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":2,"repostSize":0,"link":"https://laohu8.com/post/850404496","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","TASK":"TaskUs Inc.","EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294371,"gmtCreate":1634947239536,"gmtModify":1634947239578,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850404496,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6249428,"gmtCreate":1634615051166,"gmtModify":1634631651885,"authorId":3582075354763697,"author":{"id":3582075354763697,"idStr":"3582075354763697","authorId":3582075354763697,"name":"Blackbunny","avatar":"https://static.tigerbbs.com/7c19a775624a3a537472a142b0aaf453","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850404496,"type":1,"supId":0,"prevId":0,"content":"<u>done</u>","text":"<u>done</u>","html":"<u>done</u>"}],"langContent":"CN"},{"id":850401221,"gmtCreate":1634612875138,"gmtModify":1634612877550,"author":{"id":"3575974639321365","authorId":"3575974639321365","name":"Chris68","avatar":"https://static.tigerbbs.com/1ae39a12c3ba237f3b001689ec9a549b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"authorIdStr":"3575974639321365","idStr":"3575974639321365"},"htmlText":"Good to know&nbsp;","listText":"Good to know&nbsp;","text":"Good to know","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850401221","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","TASK":"TaskUs Inc.","EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6249127,"gmtCreate":1634612881977,"gmtModify":1634631672501,"authorId":3575974639321365,"author":{"id":3575974639321365,"idStr":"3575974639321365","authorId":3575974639321365,"name":"Chris68","avatar":"https://static.tigerbbs.com/1ae39a12c3ba237f3b001689ec9a549b","vip":1,"crmLevel":3,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850401221,"type":1,"supId":0,"prevId":0,"content":"Yup","text":"Yup","html":"Yup"}],"langContent":"CN"},{"id":850577656,"gmtCreate":1634612424203,"gmtModify":1634612424597,"author":{"id":"3583478720415511","authorId":"3583478720415511","name":"Bentofighter","avatar":"https://static.tigerbbs.com/3d3b444e1397cd8d1ec1b18c5c8c5db5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"authorIdStr":"3583478720415511","idStr":"3583478720415511"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/850577656","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","TASK":"TaskUs Inc.","EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294375,"gmtCreate":1634947247085,"gmtModify":1634947247195,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850577656,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."}],"langContent":"CN"},{"id":850549704,"gmtCreate":1634610961478,"gmtModify":1634610961603,"author":{"id":"3582080374471215","authorId":"3582080374471215","name":"Cindyoxy","avatar":"https://static.tigerbbs.com/6ce8843c8a2fd64a899130762430331d","vip":1,"crmLevel":2,"crmLevelSwitch":0,"authorIdStr":"3582080374471215","idStr":"3582080374471215"},"htmlText":"Like pls","listText":"Like pls","text":"Like pls","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":3,"repostSize":0,"link":"https://laohu8.com/post/850549704","repostId":2176774120,"repostType":4,"repost":{"id":"2176774120","pubTimestamp":1634599410,"share":"https://www.laohu8.com/m/news/2176774120?lang=&edition=full","pubTime":"2021-10-19 07:23","market":"us","language":"en","title":"After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more","url":"https://stock-news.laohu8.com/highlight/detail?id=2176774120","media":"StreetInsider","summary":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced ","content":"<p>After-Hours Stock Movers:</p>\n<p><a href=\"https://laohu8.com/S/ETTX\">Entasis Therapeutics Holdings Inc.</a> (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.</p>\n<p><a href=\"https://laohu8.com/S/DRMAW\">Dermata Therapeutics, Inc.</a> (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.</p>\n<p>TaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.</p>\n<p>EverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.</p>\n<p><a href=\"https://laohu8.com/S/STLD\">Steel Dynamics</a> (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.</p>","source":"highlight_streetinsider","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>After-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAfter-Hours Stock Movers: Entasis Therapeutics,Dermata Therapeutics,TaskUs and more\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-19 07:23 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.streetinsider.com/dr/news.php?id=19073229><strong>StreetInsider</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and...</p>\n\n<a href=\"https://www.streetinsider.com/dr/news.php?id=19073229\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"ETTX":"Entasis Therapeutics Holdings Inc.","STLD":"Steel Dynamics","TASK":"TaskUs Inc.","EVER":"Everquote Inc.","DRMA":"Dermata Therapeutics Inc"},"source_url":"https://www.streetinsider.com/dr/news.php?id=19073229","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2176774120","content_text":"After-Hours Stock Movers:\nEntasis Therapeutics Holdings Inc. (Nasdaq: ETTX) 22.2% HIGHER; announced topline results from its ATTACK triala global Phase 3 registrational trial evaluating the safety and efficacy of SUL-DUR versus colistin in patients with infections caused by Acinetobacter baumannii. SUL-DUR met the primary endpoint of 28-day all-cause mortality in patients with carbapenem-resistant Acinetobacter infections (CRABC m-MITT* population in Part A of the study), demonstrating statistical non-inferiority versus colistin. Mortality analyses favored SUL-DUR versus colistin in CRABC m-MITT and all study populations included in the topline results. At Test of Cure, there was a statistically significant difference in clinical response favoring SUL-DUR over colistin. SUL-DUR met the primary safety objective of the study achieving statistically significant reduction in nephrotoxicity.\nDermata Therapeutics, Inc. (NASDAQ: DRMA) 13.4% HIGHER; announced positive topline results from its Phase 1b trial of DMT310 in 30 patients as a once-weekly topical application for the treatment of mild-to-moderate psoriasis. DMT310 is Dermata's lead product candidate, with both mechanical and chemical mechanisms of action, currently being investigated to treat multiple inflammatory skin conditions, including acne, psoriasis, and rosacea.\nTaskUs, Inc. (NASDAQ: TASK) 6.5% LOWER; announced today that certain of its stockholders have commenced an underwritten public offering of 10,000,000 shares of TaskUs Class A common stock. In connection with the offering, the selling stockholders intend to grant the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of Class A common stock.\nEverQuote, Inc. (Nasdaq: EVER) 5.6% LOWER; Total revenue is expected to be in the range of $106.5 $107.5 million, compared to guidance of $109 - $111 million.\nSteel Dynamics (NASDAQ: STLD) 1.6% HIGHER; Q3 results, with EPS coming in at $4.96, beating the consensus estimate of $4.57. Quarterly revenue was a record $5.1 billion (vs. $2.3 billion in Q3/20), better than the consensus estimate of $4.98 billion.","news_type":1},"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6294380,"gmtCreate":1634947255303,"gmtModify":1634947255332,"authorId":3567307840510045,"author":{"id":3567307840510045,"idStr":"3567307840510045","authorId":3567307840510045,"name":"JeremyKok","avatar":"https://static.tigerbbs.com/01b03a485f83b6b2615fad8ac9b87bf4","vip":1,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850549704,"type":1,"supId":0,"prevId":0,"content":"hi. please like and comment back. thank you.","text":"hi. please like and comment back. thank you.","html":"hi. please like and comment back. thank you."},{"id":6249027,"gmtCreate":1634612429882,"gmtModify":1634631680265,"authorId":3583478720415511,"author":{"id":3583478720415511,"idStr":"3583478720415511","authorId":3583478720415511,"name":"Bentofighter","avatar":"https://static.tigerbbs.com/3d3b444e1397cd8d1ec1b18c5c8c5db5","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850549704,"type":1,"supId":0,"prevId":0,"content":"Ok","text":"Ok","html":"Ok"},{"id":6249210,"gmtCreate":1634613444936,"gmtModify":1634631668039,"authorId":3576017931077934,"author":{"id":3576017931077934,"idStr":"3576017931077934","authorId":3576017931077934,"name":"LennartM","avatar":"https://static.tigerbbs.com/2b888cf8f0c645e538df3ec026d3db37","vip":1,"crmLevel":4,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":850549704,"type":1,"supId":0,"prevId":0,"content":"done","text":"done","html":"done"}],"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":255,"commentSize":30,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2176774120"}